vs
Better Home & Finance Holding Co（BETR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Better Home & Finance Holding Co的季度营收约是REGENXBIO Inc.的1.5倍（$44.3M vs $30.3M），REGENXBIO Inc.净利率更高（-221.3% vs -3349.0%，领先3127.6%），Better Home & Finance Holding Co同比增速更快（77.4% vs 43.0%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-167.8M），过去两年Better Home & Finance Holding Co的营收复合增速更高（41.1% vs 39.4%）
巴贾吉金融有限公司是印度一家可吸收存款的非银行金融机构，总部位于普纳。截至2025年9月，该公司拥有1.1064亿客户，管理资产规模达46225亿卢比，约合550亿美元，是印度知名的非银行金融服务商。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BETR vs RGNX — 直观对比
营收规模更大
BETR
是对方的1.5倍
$30.3M
营收增速更快
BETR
高出34.4%
43.0%
净利率更高
RGNX
高出3127.6%
-3349.0%
自由现金流更多
RGNX
多$115.0M
$-167.8M
两年增速更快
BETR
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.3M | $30.3M |
| 净利润 | $-39.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -3376.8% | -190.0% |
| 净利率 | -3349.0% | -221.3% |
| 营收同比 | 77.4% | 43.0% |
| 净利润同比 | 32.6% | -31.2% |
| 每股收益（稀释后） | $-2.52 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BETRRGNX
| Q4 25 | $44.3M | $30.3M | ||
| Q3 25 | $43.9M | $29.7M | ||
| Q2 25 | $44.1M | $21.4M | ||
| Q1 25 | $32.6M | $89.0M | ||
| Q4 24 | $25.0M | $21.2M | ||
| Q3 24 | $29.0M | $24.2M | ||
| Q2 24 | $32.3M | $22.3M | ||
| Q1 24 | $22.3M | $15.6M |
净利润BETRRGNX
| Q4 25 | $-39.9M | $-67.1M | ||
| Q3 25 | $-39.1M | $-61.9M | ||
| Q2 25 | $-36.3M | $-70.9M | ||
| Q1 25 | $-50.6M | $6.1M | ||
| Q4 24 | $-59.2M | $-51.2M | ||
| Q3 24 | $-54.2M | $-59.6M | ||
| Q2 24 | $-41.4M | $-53.0M | ||
| Q1 24 | $-51.5M | $-63.3M |
毛利率BETRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BETRRGNX
| Q4 25 | -3376.8% | -190.0% | ||
| Q3 25 | -88.9% | -176.3% | ||
| Q2 25 | -81.9% | -296.3% | ||
| Q1 25 | -154.9% | 13.6% | ||
| Q4 24 | -1428.3% | -242.1% | ||
| Q3 24 | -186.5% | -256.6% | ||
| Q2 24 | -127.6% | -251.3% | ||
| Q1 24 | -230.8% | -408.8% |
净利率BETRRGNX
| Q4 25 | -3349.0% | -221.3% | ||
| Q3 25 | -89.2% | -208.3% | ||
| Q2 25 | -82.2% | -331.8% | ||
| Q1 25 | -155.3% | 6.8% | ||
| Q4 24 | -1437.5% | -241.3% | ||
| Q3 24 | -187.0% | -246.3% | ||
| Q2 24 | -128.2% | -237.7% | ||
| Q1 24 | -231.4% | -405.4% |
每股收益（稀释后）BETRRGNX
| Q4 25 | $-2.52 | $-1.30 | ||
| Q3 25 | $-2.56 | $-1.20 | ||
| Q2 25 | $-2.39 | $-1.38 | ||
| Q1 25 | $-3.33 | $0.12 | ||
| Q4 24 | $-3.92 | $-0.99 | ||
| Q3 24 | $-3.58 | $-1.17 | ||
| Q2 24 | $-2.74 | $-1.05 | ||
| Q1 24 | $-3.41 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $203.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $37.2M | $102.7M |
| 总资产 | $1.5B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BETRRGNX
| Q4 25 | $203.4M | $230.1M | ||
| Q3 25 | $205.8M | $274.2M | ||
| Q2 25 | $221.5M | $323.3M | ||
| Q1 25 | $228.0M | $267.9M | ||
| Q4 24 | $264.9M | $234.7M | ||
| Q3 24 | $262.1M | $255.5M | ||
| Q2 24 | $378.8M | $290.4M | ||
| Q1 24 | $482.6M | $338.7M |
股东权益BETRRGNX
| Q4 25 | $37.2M | $102.7M | ||
| Q3 25 | $41.9M | $161.5M | ||
| Q2 25 | $76.6M | $213.7M | ||
| Q1 25 | $-102.1M | $274.2M | ||
| Q4 24 | $-58.2M | $259.7M | ||
| Q3 24 | $388.0K | $301.4M | ||
| Q2 24 | $44.9M | $348.3M | ||
| Q1 24 | $76.3M | $390.7M |
总资产BETRRGNX
| Q4 25 | $1.5B | $453.0M | ||
| Q3 25 | $1.4B | $525.2M | ||
| Q2 25 | $1.2B | $581.0M | ||
| Q1 25 | $1.0B | $490.9M | ||
| Q4 24 | $913.1M | $466.0M | ||
| Q3 24 | $845.2M | $519.1M | ||
| Q2 24 | $957.9M | $569.4M | ||
| Q1 24 | $841.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-166.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-167.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | -378.6% | -174.0% |
| 资本支出强度资本支出/营收 | 2.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-277.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BETRRGNX
| Q4 25 | $-166.6M | $-52.3M | ||
| Q3 25 | $4.2M | $-56.0M | ||
| Q2 25 | $-56.3M | $-49.3M | ||
| Q1 25 | $-57.2M | $33.6M | ||
| Q4 24 | $-380.0M | $-31.6M | ||
| Q3 24 | $-10.6M | $-40.5M | ||
| Q2 24 | $-220.6M | $-45.5M | ||
| Q1 24 | $-42.8M | $-55.5M |
自由现金流BETRRGNX
| Q4 25 | $-167.8M | $-52.8M | ||
| Q3 25 | $4.0M | $-56.5M | ||
| Q2 25 | $-56.7M | $-49.7M | ||
| Q1 25 | $-57.4M | $32.6M | ||
| Q4 24 | $-383.4M | $-32.7M | ||
| Q3 24 | $-11.7M | $-40.9M | ||
| Q2 24 | $-221.8M | $-46.0M | ||
| Q1 24 | $-43.3M | $-56.0M |
自由现金流率BETRRGNX
| Q4 25 | -378.6% | -174.0% | ||
| Q3 25 | 9.1% | -189.9% | ||
| Q2 25 | -128.5% | -232.8% | ||
| Q1 25 | -176.3% | 36.6% | ||
| Q4 24 | -1534.6% | -154.2% | ||
| Q3 24 | -40.5% | -168.9% | ||
| Q2 24 | -687.6% | -206.2% | ||
| Q1 24 | -194.5% | -358.5% |
资本支出强度BETRRGNX
| Q4 25 | 2.7% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 13.6% | 5.1% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 3.9% | 2.1% | ||
| Q1 24 | 2.1% | 3.6% |
现金转化率BETRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BETR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
